{"entity":{"id":"nct06686030","kind":"trial","name":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","aka":[],"tldr":"A phase 2 trial of Ivonescimab, Olaparib in ovarian cancer, run by Akeso, now recruiting.","summary":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer is a phase 2 interventional study registered as NCT06686030 by Akeso, with 150 participants planned, started 2025-02-17 and due to reach its primary completion in 2027-10. Interventions recorded: AK112 low dose, Chemotherapy, Olaparib, AK112 high dose. Conditions listed: Platinum-sensitive Ovarian Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06686030","url":"https://clinicaltrials.gov/study/NCT06686030"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["ivonescimab","olaparib"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06686030","phase":"2","setting":"An Exploratory, Multi-cohort Phase II Study of Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","sponsor":"Akeso","enrolled":150,"outcomes":[]},"route":"/trials/nct06686030/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}